Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay N Cohn

Circulation

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Circulation|November 6, 2002
Sympathetic nervous system in heart failureJay N Cohn
Circulation|February 8, 2006
Arterial stiffness, vascular disease, and risk of cardiovascular eventsJay N Cohn
Circulation|February 8, 2021
Biostatistics Versus PathophysiologyJay N Cohn
Circulation|November 6, 2013
The message is clear: prevent as well as treat acute myocardial infarctionJay N Cohn
Circulation|May 19, 2004
The James B. Herrick Award Lecture. 2003. Clinical research: whose agenda is it?Jay N Cohn
Circulation|July 1, 2004
Introduction to surrogate markersJay N Cohn
Circulation|July 1, 2004
Surrogate markers for cardiovascular disease: functional markersJay N Cohn, Arshed A Quyyumi, Norman K Hollenberg, et al.
Circulation|August 27, 2003
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure TrialJay N Cohn, Inder S Anand, Roberto Latini, et al.
Circulation|October 7, 2009
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failureInder S Anand, Kalkidan Bishu, Thomas S Rector, et al.
Circulation|April 17, 2002
Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failureKarl Swedberg, Michael R Bristow, Jay N Cohn, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Circulation|November 6, 2002
Sympathetic nervous system in heart failureJay N Cohn
Circulation|February 8, 2006
Arterial stiffness, vascular disease, and risk of cardiovascular eventsJay N Cohn
Circulation|February 8, 2021
Biostatistics Versus PathophysiologyJay N Cohn
Circulation|November 6, 2013
The message is clear: prevent as well as treat acute myocardial infarctionJay N Cohn
Circulation|May 19, 2004
The James B. Herrick Award Lecture. 2003. Clinical research: whose agenda is it?Jay N Cohn
Circulation|July 1, 2004
Introduction to surrogate markersJay N Cohn
Circulation|July 1, 2004
Surrogate markers for cardiovascular disease: functional markersJay N Cohn, Arshed A Quyyumi, Norman K Hollenberg, et al.
Circulation|August 27, 2003
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure TrialJay N Cohn, Inder S Anand, Roberto Latini, et al.
Circulation|October 7, 2009
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failureInder S Anand, Kalkidan Bishu, Thomas S Rector, et al.
Circulation|April 17, 2002
Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failureKarl Swedberg, Michael R Bristow, Jay N Cohn, et al.
Pageof 2